Effects of ibandronate on inflammation in mouse antigen-induced arthritis

Inflammation Research

Volumn 52, Issue 5, 2003, Pages 221-226

  Zysk, S P ^a   Durr H R ^b   Gebhard, H H ^a   Schmitt Sody, M ^a   Refior, H J ^a   Messmer, K ^a   Veihelmann, A ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Antigen induced arthritis; Bisphosphonates; Ibandronate; Intravital microscopy; Synovial microcirculation

Indexed keywords

ANTIGEN; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CELL INTERACTION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; ERYTHROCYTE; FEMALE; FLUORESCENCE MICROSCOPY; INFLAMMATION; LEUKOCYTE; LEUKOCYTE ADHERENCE; MOUSE; MOUSE STRAIN; NONHUMAN; PATELLA TENDON;

EID: 0038174684     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110300075     Document Type: Article

References (29)

1. Thiebaud D, Burckhardt P, Melchior J, Eckert P, Jacquet AF, Schnyder P et al. Two years' effectiveness of intravenous pamidronate (ADP) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporosis Int 1994; 4: 76-83.
2. Pecherstorfer M, Herrmann Z, Body JJ, Manegold C, Degardin M, Clemens MR et al. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol. 1996; 14: 268-76.
3. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998; 16: 593-602.
4. Miller PD. Bisphosphonates for the prevention and treatment of corticosteroid-induced osteoporosis. Osteoporos Int 2001 Suppl. 3: S3-10.
5. Adachi JD, Bensen WG, Brown J et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997; 337: 382-7.
6. Reid IR, Heap SW, King AR, Ibbertson HK. Two-year follow-up of bisphosphonate (ADP) treatment in steroid-induced osteoporosis. Lancet 1988; II: 1144
7. Yilmaz L, Ozoran K, Gunduz OH, Ucan H, Yucel M. Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids. Rheumatol Int. 2001; 20: 65-9.
8. Mühlbauer RC, Bauss F. Schenk R, Janner M, Bosies E, Strein K et al. BM 21.0955, a new bisphosphonate to inhibit bone resorption. J Bone Mineral Res 1991; 6: 1003-11.
9. Green JR, Müller GK, Jaeggi KA. Preclinical pharmacology of CGP 42'466, a new, potent, heterocyclic bisphosphonate compound. J Bone Mineral Res 1994; 9: 745-51.
10. Nakamura M, Ando T, Abe M, Kumagai K, Endo Y. Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice. Br J Pharm 1996; 119: 205-12.
11. rd Ed. Parthenon Publishing Group, 1997; NewYork, NY, USA.
12. Adami A, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987; 41: 326-31.
13. Fitton A, Mc Tavish D. Pamidronate. A review of ist pharmacological properties and therapeutic efficacy in resorptive bone desease. Drugs 1991; 41: 289-318.
14. O'Doherty DP, Gertz BJ, Tindale W, Sciberras DG, Survill TT, Kanis JA. Effects of five daily 1 h infusions of alendronate in Paget's disease of bone. J Bone Mineral Res 1992; 7: 81-7.
15. Sauty A, Pecherstorfer M, Zimmer-Roth I, Fioroni P, Juillerat L, Markert M et al. Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone, 1996; 18: 133-9.
16. Mönkkönen J, Similä J, Rogers MJ. Effects of tiludronate on the secretion of proinflammatory cytokines and nitric oxide from macrophages in vitro. Life Sciences 1998; 62: 95-102.
17. Pioli G, Hughes DE, Mian A, Aarden L, Meager A, Chapman K et al. Bisphosphonatea stimulate the production of cytokines by human peripheral blood mononuclear cells in vitro. Calcif Tissue Int 1990; 46 (suppl 2): A54
18. Schweitzer DH, Oostendorp-Van de Ruit M, Van der Pluijm G, Löwik CWGM, Papapoulos SE. Interleukin-6 and the acute response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminihydroxypropylidene bisphosphonste. J Bone Miner Res 1995; 10: 956-62.
19. Wüster C, Schöter KH, Thiebaud D, Manegold C, Krahl D, Clemens MR et al. Methylpentylaminoopropylidenebisphosphate (BM21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcaemia. Bone Miner 1993; 22: 77-85.
20. Pecherstorfer M, Jilch R, Sauty A, Horn E, Keck AV, Zimmer-Roth I et al. Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations. J Bone Miner Res. 2000; 15: 147-54.
21. Richards PJ, Amos N, Williams AS, Williams BD. Pro-inflammatory effects of the aminobisphosphonate ibandronate in vitro and in vivo. Rheumatology 1999; 38: 984-91.
22. Cruz JC, Alsina M, Craig F, Yoneda T, Anderson JL, Dallas M et al. Ibandronate decreases development and osteoclast stimulatory activity in an in vivo model of human myeloma. Experimental Haematology 2001; 29: 441-7.
23. Dallas SL, Garrett R, Oyajobi BO, Dallas MR, Boyce BF, Bauss F et al. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood 1999; 93: 1697-706.
24. Yoneda T, Sasaki A, Dunstan C. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997; 99: 2509.
25. Brackertz D, Mitchell GF, Mackay IR. Antigen-induced arthritis in various strains of mice. Arthritis Rheum 1977; 20: 841-50.
26. Veihelmann A, Szczesny G, Nolte D, Krombach F, Refior HJ, Messmer K. A novel model for the study of synovial microcirculation in the mouse knee joint. Res Exp Med 1998; 198: 43-54.
27. Harris AG, Hecht R, Peer F, Nolte D, Messmer K. An improved intravital microscopy system. Int J Microcirc Clin Exp 1997; 17: 322-7.
28. Zeintl H, Sack F-U, Intaglietta M, Messmer K. Computer-assisted leukocyte velocity measurements in intravital microscopy. Int J Microcirc Clin Exp 1989; 8: 293-302.
29. Hersmann GH, Kriegsmann J, Simon J, Hüttich Cbräuer R. Expression of cell adhesion molecules and cytokines in murine antigen-induced arthritis. Cell Adhesion and Communication 1998; 6: 69-82.